Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The global avascular necrosis market was valued at US$ 512.9 million in 2017, and is projected to record an impressive CAGR of 6.0% over the forecast period (2018-2026).
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2218
Avascular necrosis is a condition occuring when the blood flow to the head of thighbone is reduced or stopped, and is said to result in the death of cells of bone tissue in most cases. There is no known pharmaceutical cure for permanent cure of avascular necrosis. Various combinations of non-operative treatments are known to reduce symptomatic pain, such as electrical stimulation, hyperbaric oxygen therapy, shock wave therapy, physiotherapy, pharmaceuticals (such as bisphosphonates, anticoagulants, vasodilators, and lipid lowering agents), and muscle strengthening exercises.
Core decompression, osteotomies, bone and cartilage grafting, and total hip replacement surgery are the common operative treatments for avascular necrosis. Biopsy is a conclusive way to diagnose avascular necrosis but is rarely used as it requires surgery. Recovery and rehabilitation of avascular necrosis depends on surgical treatment used. Osteotomies limit activity for few months, however, a total hip replacement allows patients to begin walking with support, within days.
Special Requirements?
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2218
The progression of avascular necrosis can be delayed with the help of early diagnosis and treatment, which further minimize the need for costly and invasive procedures. According to the Chinese Medical Journal 2015 study, direct cost to patients for undergoing primary total hip arthroplasty per hip without revision is between US$ 8000 and US$ 10,000 in China. The key market contenders have been focusing on the development of effective and inexpensive therapies for treating this condition. For instance, Bone Therapeutics and Enzo Biochem, Inc. focuses on gene regulation and cell-based product treatment, which is expected to increase avascular necrosis market revenue.
Browse Press Release: https://bit.ly/3cOmJKF
Key Takeaways:
- As per the 2015 data compiled by the National Organization for Rare Disorders, avascular necrosis is one of the rarest diseases in the world, which is known to affect at least one of every 2,000 people.
- Asia Pacific is anticipated to emerge as the most prominent region in the global avascular necrosis market over the forecast timeline, on account of the high prevalence of non-traumatic avascular necrosis of femoral head in the region. According to the Clinical Orthopedics and Related Research, 2010, about 2500 to 3300 new cases of non-traumatic avascular necrosis of the femoral head are reported in Japan annually.
- The renowned companies operating in the global avascular necrosis market include Bone Therapeutics, Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon Inc., Eli Lilly and Company, Grifols SA, Integra LifeSciences Corporation, K-Stemcell Co Ltd., Medtronic Plc, Merck KGaA, Pfizer Inc., Sanofi SA, Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2218
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
